There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN – Research Report) and Surgery ...

In this photo illustration, the Range Resources company logo is seen displayed ... More on a smartphone screen. (Photo ...

Capital Group Private Client Services Inc. reduced its Regeneron holdings by 17.6% in Q4, offloading 19,565 shares, but still ...

We recently published a list of the 11 Most Promising Penny Stocks According to Analysts. In this article, we are going to ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Cerity Partners gave Regeneron a small but mighty vote of confidence, upping their stake by 3.3% in the fourth quarter. They ...

Looking back on immuno-oncology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Regeneron ...

In a report released on April 11, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron (REGN – Research Report), with a ...

Since announcing a slew of global "reciprocal" tariffs on Wednesday, April 2, stock prices worldwide have seen alarmingly sharp decreases, wreaking havoc on millions of Americans' retirement ...

While NASDAQ stocks were mostly mixed on Monday, Apple stock remained relatively weak. From its 52-week high of $260.10, the Apple share price has fallen around 30%. Corrections of 20% in Apple ...